October 30, 2020

Volume X, Number 304

Advertisement

October 30, 2020

Subscribe to Latest Legal News and Analysis

October 29, 2020

Subscribe to Latest Legal News and Analysis

October 28, 2020

Subscribe to Latest Legal News and Analysis

October 27, 2020

Subscribe to Latest Legal News and Analysis

Parallel Claims: Exact Contours Will Continue to Be Litigated

In Riegel v. Medtronic, Inc., 552 U.S. 312, 128 S. Ct. 999 (2008), decided in February 2008, the United States Supreme Court held that the Medical Device Amendments (“MDA”) to the Food Drug and Cosmetic Act (“FDCA”) expressly pre-empted common law state claims involving Class III medical devices that had received FDA pre-market approval. Relying on an express pre-emption clause contained in the MDA, 21 U.S.C. Section 360k(a), the Court held that state lawsuits were expressly pre-empted because they would impose requirements on Class III medical device manufacturers that were “different from, or in addition to,” the requirements already imposed by the FDA. But, relying on language in Medtronic v. Lohr, 518 U.S. 470, 495 (1996), the Court stopped just short of holding that all personal injury actions involving Class III medical devices were expressly pre-empted. As the Court explained:

 
Thus, § 360k does not prevent a State from providing a damages remedy for claims premised on a violation of FDA regulations; the state duties in such a case “parallel,” rather than add to, federal requirements. 
Riegel, 128 S. Ct. at 1011
 
With this single sentence, the Supreme Court recognized a new type of claim commonly referred to as the “parallel claim.” The Court, however, provided almost no guidance on the exact nature and scope of such a claim. Over the 20 months since Riegel was decided, numerous plaintiffs have seized on this language and characterized their claims as parallel claims, trying to avoid Riegel’s pre-emption. In response, trial courts, mostly in the federal arena, have had to determine what constitutes a permissible parallel claim. Although this area of law is still evolving, the validity of certain types of parallel claims has been addressed, and some practical guidance can be drawn from these cases.
 

Fraud on the FDA and Other Claims of Violating FDA Reporting Requirements

 
Since Riegel, some plaintiffs have tried to create a parallel claim by alleging that the defendant violated FDA regulations by not disclosing certain safety information to the FDA as part of the pre-market approval process, or by failing to properly report post-market adverse events. The Supreme Court in Buckman Co. v. Pl.’s Legal Committee, 531 U.S. 341, 352-53 (2001), previously ruled that the FDCA does not provide individuals with a private right of action, and that these types of claims are barred by implied pre-emption principles. Riegel did not change Buckman’s holding; there is still no independent cause of action under federal law for alleged violations of the FDCA or FDA regulations. See, e.g., Covert v. Stryker Corp., 2009 WL 2424559 (M.D.N.C. Aug. 5, 2009). For this reason, in addition to being barred by implied pre-emption principles, these types of claims for alleged violations of FDA reporting regulations have also been held to be barred under Riegel’s express pre-emption principles unless there is some state law basis for recovery. See, e.g., Miller v. DePuy Spine, Inc., 2009 WL 1767555 (D. Nev. May 1, 2009). A valid parallel claim cannot be based solely on a violation of FDA regulations. The claim must be predicated on an existing state common law or statute that provides a basis for recovery. Therefore, unless plaintiff can refer to a state common law or statute specifically permitting recovery for violations of FDA regulations, these types of claims should be expressly preempted under Riegel.
 

Manufacturing Defect Claims

 
On the other end of the spectrum, most courts have held that manufacturing defect claims, if pled properly, may constitute a valid parallel claim. See, e.g., Delaney v. Stryker Orthopaedics, 2009 WL 564243 (D.N.J. Mar. 5, 2009) (holding that manufacturing defect claims are one of the few types of claims that may not be pre-empted under Riegel). Courts have generally permitted these types of claims to proceed because a typical manufacturing defect claim asserts that the defendant manufactured the product in a manner that deviated from FDA-mandated processes or specifications and therefore, the claim would not impose additional or different requirements on the manufacturer. As long as the plaintiff provides detail on how the device deviated from manufacturing processes or specifications established by the FDA, either through the premarket approval process or through Current Good Manufacturing Practice (CGMP) regulations, most courts have found that these claims are not expressly pre-empted.
 
To date, the vast majority of parallel claims that have survived motions to dismiss alleged manufacturing defect claims. See Purcel v. Advanced Bionics Corp., 2008 WL 3874713 (S.D. Tex. 2008). Some manufacturing defect claims have been dismissed, however, either because the claims were not adequately pled pursuant to Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007), or because the alleged manufacturing defect had no relation to the device at issue or to plaintiff’s injuries. Courts have made it clear that the alleged regulatory violation must be related to the device at issue, and bear some relation to plaintiff’s injury, for a parallel claim to survive a motion to dismiss.
 

Design Defect and Failure to Warn Claims

 
Thus far, the vast majority of post-Riegel decisions have dismissed plaintiffs’ design defect and failure to warn claims under Riegel’s express pre-emption principles. The reason behind these decisions is clear. Plaintiffs can no longer assert that Class III medical devices should be designed or labeled in a manner that differs from FDA approval specifications. At least one court, however, has held that a plaintiff may assert a parallel failure to warn claim in connection with the off-label use of a Class III device. In Riley v. Cordis Corp., 625 F. Supp. 2d 769 (D. Minn. 2009), the court held that plaintiff may have a valid parallel claim if the plaintiff alleged that the defendant promoted the device for off-label uses in violation of FDA regulations and failed to provide adequate warnings and instructions relating to the off-label use.
 

Express Warranty Claims

 
The biggest divergence in reported opinions discussing parallel claims involves express warranty claims. The problem exists because in Riegel, the Supreme Court did not address whether express warranty claims were pre-empted because the lower courts dismissed that claim due to a lack of evidence. Post-Riegel, some courts, including those in the Third Circuit, have held that express warranty claims are not pre-empted under Riegel because such claims “arise from voluntary representations of the parties and not from the independent operation of state law.” See Huber v. Howmedica Osteonics Corp., 2008 WL 5451072 (D.N.J. Dec. 31, 2008).
 
Other courts have addressed the express warranty issue by analyzing whether the defendant’s representations were approved or mandated by the FDA. For example, in Riley and Horowitz v. Stryker Corp., 613 F. Supp.2d 271 (E.D.N.Y. 2009), the courts held that express warranty claims were only preempted if the warranties were based on FDA approved or mandated language. The Riley court explained that express warranty claims based on representations not approved or mandated by the FDA would not impose additional or different requirements on manufacturers because federal law permits, but does not require manufacturers to provide express warranties, 625 F. Supp. 2d at 787-88. Lastly, a few courts have found that all express warranty claims are pre-empted under Riegel.
 
Although the exact contours of the parallel claim will continue to be litigated, the parallel claim doctrine is likely here to stay in some form. It is unlikely that the Supreme Court will step in any time soon to further clarify this issue. As a result, the trial and lower appellate courts will bear the burden of establishing the framework by which parallel claims involving Class III medical devices will be judged.

This communication provides general information and is not intended to provide legal advice. Should you require legal advice, you should seek the assistance of counsel.

© Copyright 2020 Sills Cummis & Gross P.C.National Law Review, Volume , Number 96
Advertisement

TRENDING LEGAL ANALYSIS

Advertisement
Advertisement

About this Author

Beth S. Rose, Sills Cummis Gross, Pharmaceutical Research Lawyer, Mass Tort Actions Attorney
Member

As seen in the 2014 Chambers USA® Guide to America’s Leading Lawyers for Business, “Beth Rose is a skilled product liability attorney with a national profile.  Sources praise her for being 'a very strategic thinker who is extremely thorough and doesn't let anything slip through the cracks.' She is particularly known for her expertise in the pharmaceutical sector."

Beth S. Rose is nationally known for her defense of pharmaceutical and medical device companies in complex product liability and mass tort litigation. She is the...

(973) 643-5877
Charles Falletta, Mass Tort Litigation Attorney, Sills Cummis Gross, Class Action Matters Lawyer
Member

Charles J. Falletta is a Member of the Sills Cummis & Gross Litigation Practice Group with extensive experience in complex commercial, technology and class action litigation, as well as product liability and mass tort litigation.

Mr. Falletta has extensive experience in litigating matters in both state and federal trial and appellate courts involving corporations and other businesses in complex litigation, including banking clients, real estate developers, an Italian multinational biotechnology company, a large international electronics...

973-643-5926
Vincent Lodato Litigation Attorney Sills Cummis Gross Law Firm
Of Counsel

Vincent R. Lodato is an Associate in the Firm's Litigation Practice Group. Mr. Lodato’s practice concentrates on defending product liability matters including cases involving medical devices, pharmaceuticals and consumer products. His experience includes serving as member of the litigation team defending a pharmaceutical company in personal injury cases involving a drug used to treat Parkinson's disease. Mr. Lodato is also a member of a national counsel team defending a pharmaceutical company in the hormone replacement therapy (HRT) litigation. Mr. Lodato was also a member of a national...

973-643-5891
Advertisement
Advertisement